SBIR/STTR Research Award

Heterogeneous Photocatalytic System for Water Remediation

Award identifier d194a1291850a8bc2d99a37668cff91fd9d02b7ad157bbc4690a132d9c3fab50Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

STTR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ELTRON RESEARCH & DEVELOPMENT, INCORPORATED
Proposal award date
Not reported
Contract end date
Not reported
UEI
HJ7KXNJ9CV48
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We have defined a Phase I program for establishing a system that will destroy pharmaceuticals in drinking water by leveraging Eltron's PeroxEgen and proprietary photocatalysts which will be developed in Phase I research. PeroxEgen is an H2O2 and peracetic acid (PAA) generating device that is nearing commercial readiness. Wastewater, doped with PeroxEgen -generated H2O2/PAA, will come into contact with the photocatalysts, ensuring destructive oxidation of the target pharmaceutical. Catalyst development is one of Eltron's core strengths. We have developed more than 30 proprietary catalytic materials. On March 9, 2008, the Associated Press announced that an investigation led by the AP National Investigative Team reveals that pharmaceuticals and over-the-counter medicines are present in the drinking water supplied to at least 41 million Americans. While water utilities companies at this time insist that the water is safe, concern exists over the long-term health effects that will result from ingesting antibiotics, anticonvulsants, mood stabilizers, sex hormones and a number of other drugs. Gender-reversal of fish living in municipal waters containing as low as five parts per trillion of estradiol is one of the more high-profile examples of the effects that have been documented. In a seminal study by E. Michael Thurman et al., it was observed that subtle, chronic effects from low-level environmental exposure to select organic wastewater contaminants appear to be of concern. Furthermore, the EPA has funded a study by Johns Hopkins University to assess the impact of pharmaceuticals and antiseptics on drinking water. Although regulatory mandates for removing this newly detected family of pollutants don't exist today, the fact that studies are underway indicates that such regulations could soon be in effect. We believe that they will. [Even if they are not, the public will increasingly question water quality specific to these new chemical contaminants.] The University of Colorado's (CU) Department of Civil, Environmental and Architectural Engineering has agreed to consult on the program, providing the expertise of Prof. Karl Linden and Michael Thurman, Ph.D., Director of the Center for Environmental Mass Spectrometry (CEMS) at CU Boulder. CEMS houses instrumentation such as an Agilent Technologies Inc. liquid chromatography time-of-flight mass spectrometer (LC/TOF-MS) and LC/MS/MS ion trap. The Agilent TOF instrument is sensitive down to the attomole (1 x 10-18 mole) range, and offers better than two parts-per-million mass accuracy, which gives scientists high confidence in their data and helps them easily identify the compounds they find. Based on the skills of the research team and advanced development of PeroxEgen , we are confident that we can produce an effective, commercially viable system under phased funding by the NIH. PUBLIC HEALTH RELEVANCE: Since the enactment of the Clean Water Act (1972) and the Safe Drinking Water Act (1996), mandated water treatment strategies have evolved to protect the general population from toxins that are found in our water systems. New toxins, as well as the need for legislative action to protect us from them, evolve because we increase the consumption of pharmaceutical and personal care products (PPCPs), we have technologies that can probe to lower levels of detection, we learn about the consequences of ingesting PPCPs (even at trace levels), and we delve into the consequences of mixing numerous PPCPs. The proposed technology has the potential to address a variety of these concerns because it is able to decompose a variety of PPCPs as well as disinfect water from a variety of pathogens.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

318 SBIR/STTR records share this UEI (1983–2013). Reported award amounts total $59,197,041. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Energy, Department of Defense, National Aeronautics and Space Administration, National Science Foundation, Environmental Protection Agency, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.